AUGUST 2, 2021
Top line results of SARA-INT Phase 2 study with Sarconeos (BIO101) in Sarcopenia
JULY 12, 2021
Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101) in COVID-19 at ECCMID 2021
JULY 8, 2021
Biophytis Reinforces Leadership Teams with Three Senior Appointments Fullscreen Mode
JUNE 30, 2021
Biophytis Secures the Manufacturing of Sarconeos (BIO101) for COVID-19 with a Global CDMO & Announces the Next Milestones for the COVA Phase 2-3 Study Fullscreen Mode
JUNE 30, 2021
Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos (BIO101) in Sarcopenia will be Released by August 2021.
JUNE 18, 2021
Biophytis announces new convertible bonds financing up to €32 million with Atlas and drawing of 2 tranches under the 2020 Atlas Contract for €6 million
MAY 12, 2021
Biophytis Completed Recruitment of 155 Participants to the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19 allowing the 2nd Interim Analysis.
MAY 11, 2021
Results of the Combined General Meeting on May 10, 2021
APRIL 30, 2021
Biophytis – Second Combined General Meeting to Take Place on May 10, 2021 without the physical presence of its shareholders
APRIL 29, 2021
Biophytis receives €980,000 DeepTech Funding from BPI France for the Development of Macuneos (BIO201) in Dry AMD